Los "enredos" de las malas prácticas perece ser siempre rompen por el lado más débil, o más fuerte....Los últimos acontecimientos parecen confirmarlo...
Matthew D. Thompson, testifying today in a trial over claims by a former co-worker, said that in 2002 he pushed doctors to consider prescribing Risperdal in combination with other drugs, so-called augmentation therapy, even though government regulators hadn’t approved this use. Janssen’s training didn’t include any specific prohibitions against promoting the drug that way, he said.
“I’m not saying the company tried to hide it, but we didn’t think about augmentation in the realm of on-label or off- label at that time,” Thompson said. He said he was “probably” aware that promotion of such sales was illegal.
.../...Thompson testified he was a sales representative in the Detroit area in 2002 for a Janssen sales force whose primary product was Risperdal. In one of his notes after a doctor’s visit, Thompson wrote that he was “working intently” to get the physician to try Risperdal in combination with another drug. In another, he wrote that he had “pushed” a doctor to prescribe higher levels of Risperdal in augmentation therapy. (Ver...)
Entradas
No hay comentarios:
Publicar un comentario